GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » CanSino Biologics Inc (OTCPK:CASBF) » Definitions » Gross Profit

CASBF (CanSino Biologics) Gross Profit : $9.57 Mil (TTM As of Dec. 2024)


View and export this data going back to 2019. Start your Free Trial

What is CanSino Biologics Gross Profit?

CanSino Biologics's gross profit for the three months ended in Dec. 2024 was $0.00 Mil. CanSino Biologics's gross profit for the trailing twelve months (TTM) ended in Dec. 2024 was $9.57 Mil.

Gross Margin % is calculated as gross profit divided by its revenue. CanSino Biologics's gross profit for the three months ended in Dec. 2024 was $0.00 Mil. CanSino Biologics's Revenue for the three months ended in Dec. 2024 was $0.00 Mil. Therefore, CanSino Biologics's Gross Margin % for the quarter that ended in Dec. 2024 was N/A%.

CanSino Biologics had a gross margin of N/A% for the quarter that ended in Dec. 2024 => No sustainable competitive advantage

During the past 9 years, the highest Gross Margin % of CanSino Biologics was 70.37%. The lowest was -253.78%. And the median was 25.56%.


CanSino Biologics Gross Profit Historical Data

The historical data trend for CanSino Biologics's Gross Profit can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

CanSino Biologics Gross Profit Chart

CanSino Biologics Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24
Gross Profit
Get a 7-Day Free Trial Premium Member Only 0.73 471.31 -26.77 -122.69 79.73

CanSino Biologics Quarterly Data
Dec16 Dec17 Dec18 Jun19 Dec19 Jun20 Dec20 Jun21 Dec21 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Dec24
Gross Profit Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 106.80 -123.10 9.45 16.42 -

Competitive Comparison of CanSino Biologics's Gross Profit

For the Drug Manufacturers - Specialty & Generic subindustry, CanSino Biologics's Gross Profit, along with its competitors' market caps and Gross Profit data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


CanSino Biologics's Gross Profit Distribution in the Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, CanSino Biologics's Gross Profit distribution charts can be found below:

* The bar in red indicates where CanSino Biologics's Gross Profit falls into.


;
;

CanSino Biologics Gross Profit Calculation

Gross Profit is the different between the sale prices and the cost of buying or producing the goods.

CanSino Biologics's Gross Profit for the fiscal year that ended in Dec. 2024 is calculated as

Gross Profit (A: Dec. 2024 )=Revenue - Cost of Goods Sold
=113.297 - 33.572
=79.73

CanSino Biologics's Gross Profit for the quarter that ended in Dec. 2024 is calculated as

Gross Profit (Q: Dec. 2024 )=Revenue - Cost of Goods Sold
=0 - 0
=0.00

Gross Profit for the trailing twelve months (TTM) ended in Dec. 2024 adds up the quarterly data reported by the company within the most recent 12 months, which was $9.57 Mil.

Gross Profit is the numerator in the calculation of Gross Margin. (Note that if there's no value for Cost of Goods Sold, then Gross Margin % is not calculated.)

CanSino Biologics's Gross Margin % for the quarter that ended in Dec. 2024 is calculated as

Gross Margin % (Q: Dec. 2024 )=Gross Profit (Q: Dec. 2024 ) / Revenue (Q: Dec. 2024 )
=(Revenue - Cost of Goods Sold) / Revenue
=0.00 / 0
=N/A %

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

A positive Gross Profit is only the first step for a company to make a net profit. The gross profit needs to be big enough to also cover related labor, equipment, rental, marketing/advertising, research and development and a lot of other costs in selling the products.


CanSino Biologics  (OTCPK:CASBF) Gross Profit Explanation

Warren Buffett believes that firms with excellent long term economics tend to have consistently higher margins.

Durable competitive advantage creates a high Gross Margin % because of the freedom to price in excess of cost. Companies can be categorized by their Gross Margin %

1. Greater than 40% = Durable competitive advantage
2. Less than 40% = Competition eroding margins
3. Less than 20% = no sustainable competitive advantage
Consistency of Gross Margin is key

CanSino Biologics had a gross margin of N/A% for the quarter that ended in Dec. 2024 => No sustainable competitive advantage


CanSino Biologics Gross Profit Related Terms

Thank you for viewing the detailed overview of CanSino Biologics's Gross Profit provided by GuruFocus.com. Please click on the following links to see related term pages.


CanSino Biologics Business Description

Traded in Other Exchanges
Address
185 South Avenue, 401-420, 4th Floor, Biomedical Park, TEDA West District, Tianjin, CHN
CanSino Biologics Inc is a China-based company engaged in the research and development, manufacturing, and commercialization of vaccine products for human use. Its products are Menhycia and Menphecia; Convidecia, Convidecia Air, and XBB.1.5 Variant; Ad5-EBOV; PCV13i; PBPV; and DTcP Infant. Its geographic areas are PRC and Overseas. It generates the majority of its revenue from the PRC.